EP1515728A2 - Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind - Google Patents
Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sindInfo
- Publication number
- EP1515728A2 EP1515728A2 EP03735573A EP03735573A EP1515728A2 EP 1515728 A2 EP1515728 A2 EP 1515728A2 EP 03735573 A EP03735573 A EP 03735573A EP 03735573 A EP03735573 A EP 03735573A EP 1515728 A2 EP1515728 A2 EP 1515728A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- hydroxy
- medicament
- group
- lloprost
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
Definitions
- Bone marrow edema is associated
- the invention relates to the subject-matter set out in the patent claims, that is to say the use of orally available prostacyclin derivatives for the production of a medicament for the treatment of diseases which are associated with bone marrow edema.
- Osteonecrosis (syn .: aseptic necrosis, avascular necrosis, ischemic necrosis) is a common disease. Pain is the main symptom. In about two thirds of the patients, this pain occurs at rest. Osteonecrosis is often described as a transient process. In the spontaneous course, there is usually a complete healing after 6 to 12 months. During this period, however, the patient is exposed to severe pain, which is often not even accessible to conventional pain therapy. The incidence rates of the progression of early osteonecrosis to the end stage with pronounced bone necrosis are not known. Osteonecrosis is responsible for more than 10% of all joint replacement surgery performed annually.
- Knee osteoarthritis is a common disease that affects approximately 11-15% of people over 65 and is the most common cause of physical illness
- Osteoarthritis is defined as primarily non-inflammatory joint destruction, which begins with cartilage dying in adults and later also affects the other joint structures and progresses irreversibly. The overall course is usually progressive, but changes in phases with regard to clinical acuity. In the final stage, knee replacement is necessary.
- osteonecrosis and osteoarthritis on the hip and knee joints, but also on the shoulder, wrist and ankle. While in the treatment of osteonecrosis the surgical
- Bone marrow relief with all its disadvantages such as inpatient stay and surgery as a means of pain relief, the treatment of osteoarthritis currently consists only of symptomatic pain treatment and is insufficiently effective. It usually includes the permanent prescription of analgesics and / or anti-inflammatory drugs, combined with physiotherapy and weight relief, and possibly the intra-articular injection of anesthetics, corticoids or "cartilage building / replacing" substances. X-ray stimulation and acupuncture are also prescribed. The treatment of arthrosis has so far been limited to symptomatic treatment.
- the established therapies are unsatisfactory for both osteonecrosis and osteoarthritis due to the limitation to symptomatic treatment.
- the persistence of the pain-triggering mechanisms requires long-term treatment, which is associated with additional risks and costs.
- a causal treatment of the pain with permanent freedom from pain is therefore particularly desirable for osteoarthritis.
- the object was therefore to find a treatment for the diseases associated with bone marrow edema, in particular osteonecrosis and osteoarthritis, which did not only relate to the symptomatic treatment, i.e. pain relief, but also restores the structural integrity of the bone, and also to provide a drug that can be taken by the patient over a long period of time without the doctor's support.
- Prostacyclin derivatives especially the cyclodextrin clathrates of prostacyclin derivatives of the general formula I
- R 1 is a hydrogen atom or a Ci-C-io-alkyl radical
- W is a free or functionally modified on the hydroxy group
- X, Y independently of one another are a -CH 2 group or an oxygen atom
- Z is a hydrogen atom or a cyano group
- D is a straight-chain or branched saturated -CC 5 alkylene group
- E is a -C ⁇ C group or a direct bond
- R 2 is a straight-chain or branched, saturated C 1 -C 7 -alkyl group
- R 3 is a free or functionally modified hydroxyl group, and all optically active forms, racemates, diastereomers, mixtures of diastereomers, their clathrates, and if R is hydrogen, their salts with physiologically compatible bases solve the task.
- Treatment with orally available prostacyclin derivatives, in particular with cyclodextrin clathrates of prostacyclin derivatives of formula I is a novel therapy that not only suppresses the symptoms, i.e. the pain, but also combats the cause of osteonecrosis and osteoarthritis, and for the first time also clinic can be done independently.
- the alkyl group R 1 is straight-chain or branched alkyl groups with 1-10 carbon atoms, such as methyl, ethyl, propyl, 2-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl (tert.- Butyl), hexyl, heptyl, octyl, nonyl, decyl.
- the alkyl group R 1 can also be substituted. Examples of substituents are fluorine, chlorine or bromine atoms, phenyl, dimethylamino, diethylamino, methoxy, ethoxy.
- Alkyl groups with 1-4 carbon atoms are preferred as the alkyl group R 1 .
- the alkyl group R 2 is straight-chain or branched, reference may be made, for example, to the radicals of corresponding chain length mentioned for R 1 , and has 1-7 carbon atoms, preferably 1-3 carbon atoms, particularly preferably 1-2.
- the hydroxyl groups in R 3 and W can be functionally modified. This means esterification or etherification.
- the ethers and / or acyl radicals thus obtained are the radicals known to the person skilled in the art.
- Ether residues are e.g. Tetrahydropyranyl, tetrahydrofuranyl, methoxymethyl, methoxyethyl, ethoxyethyl, silyl ether such as e.g. Trimethylsilyl, dimethyl tert-butylsilyl, triphenylsilyl.
- Acyl radicals can be, for example, acetyl, propionyl, butyryl, benzoyl.
- X preferably has the meaning of a CH 2 group.
- Z preferably represents a hydrogen atom.
- alkylene group D straight-chain or branched saturated alkylene group with 1-5 carbon atoms are suitable. Examples include methylene, ethylene, propylene, 1-methylethylene, butylene, 1-methylpropylene, 2-methylpropylene, pentylene, 1-methylbutylene and ethylethylene. A branched alkylene group having 3 carbon atoms is preferred.
- R 1 represents a hydrogen atom
- the compounds of the formula I can also be present as salts of physiologically compatible bases.
- Both inorganic and organic bases are suitable for salt formation.
- alkali hydroxides such as sodium or
- Potassium hydroxide alkaline earth metal hydroxides such as calcium hydroxide, ammonia, amines such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine, morpholine, tris (hydroxymethyl) methylamine.
- the prostacyclin derivatives are orally available in the sense according to the invention when they can be used for oral administration after a suitable formulation.
- prostacyclin derivatives of the general formula I formulated for oral administration: cicaprost (5 - ⁇ (E) - ( 1 S, 5S, 6S, 7R) -7-hydroxy-6 - [(3S, 4S) -3-hydroxy-4-methyl-1, 6-nonadiynyl] bicyclo [3.3.0] oct-3-ylidene ⁇ -3-oxapentanoic acid), epoprostenol ((5Z, 9, 13E, 15S) -6,9-epoxy-11,15-dihydroxy-prosta-5,13-diene-1-acid), beraprost (EP 0 084856) , Ciprostene, Taprostene, Naxaprostene, CS 570, SC-39902, FCE-22509, OP 41483
- hoprost- ⁇ -cyclodextrin clathrate for the manufacture of a medicament for the treatment of osteonecrosis and osteoarthritis is a preferred subject of the invention.
- lloprost is a prostacyclin analogue which is known from EP 11 591 and can be produced by the methods disclosed therein.
- the nomenclature name for lloprost is (5 - ⁇ (1 S, 5S, 6R, 7R) -7-hydroxy-6 - [(E) - (3R, 4RS) -3-hydro) (y-4-methyl-oct- 1-en-6-ynyl] -bicyclo [3.3.0] octan-3-ylidene ⁇ -pentanoic acid).
- lloprost- ⁇ -cyclodextrin clathrate that is known from EP 259468 and can be produced by the method disclosed therein. It is known from EP 1 016 408 that prostano ⁇ de CC chemokine production are inhibitors. According to current knowledge, the mechanisms disclosed there are not relevant for bone marrow edema.
- Osteoarthritis is between 50 ⁇ g / day and 350 ⁇ g / day, preferably between 100 ⁇ g / day and 300 ⁇ g / day or between 150 ⁇ g / day and 350 ⁇ g / day, these amounts being able to be divided into several individual doses.
- Healing of the bone necrosis can be achieved within a few weeks.
- Figure 4 Case study of a patient with complete regression of an extensive bone marrow edema in the early stage of osteonecrosis.
- the control MRI was performed 2 months after the 28 day treatment with oral lloprost was completed.
- Figure 7 Equally pronounced increase in knee activity score according to Larson (point maximum 100) with double-blind administration of oral lloprost treatment and Tramadol ® treatment. The improvement continues over a 2-month therapy-free period. Data as mean values + SEM. p-values to compare the two
- Treatments prove their equivalence (Hodges-Lehmann estimator and Wilcoxon test).
- the treatment was carried out with Iloprost capsules, which were packed and labeled in accordance with the applicable GLP rules. Each capsule contained 50 ⁇ g lloprost.
- lloprost was administered in a dose of 3x50 ⁇ g lloprost per day, which could be increased individually from day 4 up to a maximum dose of 3x100 ⁇ g lloprost per day:
- this dosage could be achieved either by increasing the single dose (maximum: 3x100 ⁇ g lloprost per day) or by shortening the free interval (minimum: 2 h, i.e. 6x50 ⁇ g lloprost per day).
- the dosage could be reduced at any time up to a minimum dose of 2x50 ⁇ g lloprost a day.
- the duration of treatment was one month. Pain-relieving drugs previously administered should be discontinued before the start of the study.
- lloprost Adverse events and side effects were recorded as safety parameters.
- Known side effects of lloprost include symptoms such as headache, flushing, nausea, vomiting and diarrhea.
- the study medication was administered in a dose of 3x1 capsule per day, which was administered individually from day 4 onwards
- Enhancement of therapy success (pain relief) to a maximum Dosage of 3x2 capsules a day could be increased.
- the dosage could be reduced at any time to a minimum dose of 2x1 capsules a day.
- the duration of treatment was one month, followed by a treatment-free follow-up period of two months. Pain-relieving drugs previously administered should be discontinued before the start of the study.
- Complaints such as headache, facial flushing, nausea, vomiting and diarrhea.
- Visit 6 took place on day 56 or after 4 treatment-free weeks.
- Visit 7 took place on day 84 or after 8 treatment-free weeks.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10225551 | 2002-06-06 | ||
DE10225551A DE10225551A1 (de) | 2002-06-06 | 2002-06-06 | Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind |
PCT/EP2003/005990 WO2003103681A2 (de) | 2002-06-06 | 2003-06-05 | Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziert sind |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1515728A2 true EP1515728A2 (de) | 2005-03-23 |
Family
ID=29594336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03735573A Withdrawn EP1515728A2 (de) | 2002-06-06 | 2003-06-05 | Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1515728A2 (de) |
JP (1) | JP2005536476A (de) |
KR (1) | KR20050007591A (de) |
CN (1) | CN1658882A (de) |
AU (1) | AU2003236715A1 (de) |
CA (1) | CA2488861A1 (de) |
DE (1) | DE10225551A1 (de) |
WO (1) | WO2003103681A2 (de) |
ZA (1) | ZA200500097B (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8318802B2 (en) * | 2006-02-03 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Epoprostenol formulation and method of making thereof |
TWI520740B (zh) * | 2011-02-02 | 2016-02-11 | 模範健康科技私人企業有限公司 | 利用多硫酸化多醣之骨髓水腫(水腫)的治療 |
CN111278464A (zh) * | 2017-08-31 | 2020-06-12 | 柏林夏瑞蒂医科大学 | 用于防止妥协性患者中肌肉骨骼损伤愈合不良的免疫调节 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3608088C2 (de) * | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
CA2152403C (en) * | 1992-08-07 | 2005-06-21 | Peter Scholz | Use of prostane derivatives of formulae i and ii for the production of a medicament for the treatment of chronic polyarthritis |
WO1999013880A1 (fr) * | 1997-09-16 | 1999-03-25 | Toray Industries, Inc. | Inhibiteur de la production de chemokine c-c |
AU2002212996A1 (en) * | 2000-09-28 | 2002-04-08 | Non-Invasive Monitoring Systems, Inc. | External addition of pulses to fluid channels of body to release or suppress endothelial mediators and to determine effectiveness of such intervention |
-
2002
- 2002-06-06 DE DE10225551A patent/DE10225551A1/de not_active Ceased
-
2003
- 2003-06-05 CN CN038129760A patent/CN1658882A/zh active Pending
- 2003-06-05 KR KR10-2004-7019813A patent/KR20050007591A/ko not_active Application Discontinuation
- 2003-06-05 WO PCT/EP2003/005990 patent/WO2003103681A2/de not_active Application Discontinuation
- 2003-06-05 EP EP03735573A patent/EP1515728A2/de not_active Withdrawn
- 2003-06-05 CA CA002488861A patent/CA2488861A1/en not_active Abandoned
- 2003-06-05 JP JP2004510800A patent/JP2005536476A/ja active Pending
- 2003-06-05 AU AU2003236715A patent/AU2003236715A1/en not_active Abandoned
-
2005
- 2005-01-05 ZA ZA200500097A patent/ZA200500097B/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO03103681A2 * |
Also Published As
Publication number | Publication date |
---|---|
KR20050007591A (ko) | 2005-01-19 |
WO2003103681A2 (de) | 2003-12-18 |
CN1658882A (zh) | 2005-08-24 |
ZA200500097B (en) | 2006-06-28 |
DE10225551A1 (de) | 2003-12-24 |
JP2005536476A (ja) | 2005-12-02 |
CA2488861A1 (en) | 2003-12-18 |
AU2003236715A1 (en) | 2003-12-22 |
WO2003103681A3 (de) | 2004-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69431729T2 (de) | Bromocryptin enthaltende mittel mit beschleunigter freisetzung | |
DE69404675T2 (de) | Pharmazeutische zusammensetzung zur intranasalen verabreichung von hydroxocobalamin | |
DE69423146T2 (de) | Parathyroid-Hormon und Raloxifen zum Vermehren von Knochenmasse | |
DE69629184T2 (de) | Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus | |
DE69737066T2 (de) | Verwendung von aktivem Vitamin D analog zur Behandlung von Prostataerkrankungen | |
DE69722401T2 (de) | Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods | |
DE69430903T2 (de) | Behandlung von periodontitis mit misoprostol | |
DE69201725T2 (de) | Behandlungsmethoden für osteoporose. | |
DE69125714T2 (de) | Zusammensetzung für die behandlung des humanen prostata adenokarzinom | |
DE69526937T2 (de) | Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen | |
WO2001060407A2 (de) | Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis | |
EP0413171A1 (de) | Mittel zur Behandlung von schweren Schmerzzuständen und Verfahren zu ihrer Herstellung | |
WO1998035682A1 (de) | Mittel zur hormonalen kontrazeption und/oder behandlung und/oder prophylaxe von tumoren der brustdrüsen mit drei hormonkomponente | |
EP0521388B1 (de) | Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung | |
DE60029340T2 (de) | Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran | |
DE4328217C2 (de) | Therapeutisches System zur Behandlung der Psoriasis | |
EP1830835A1 (de) | Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels | |
DE3033545A1 (de) | Verwendung bekannter antiallergener mittel bei der bekaempfung von pathologischen mineralresorptionszustaenden | |
DE69431986T2 (de) | Verwendung von granisetron zur behandlung von postoperativer übelkeit und erbrechen | |
EP0179421A2 (de) | Antigestagene, Glukokortikoide und Prostaglandine zur Geburtseinleitung oder für den Schwangerschaftsabbruch | |
EP1515728A2 (de) | Verwendung von oral verfügbaren prostazyklinderivaten für die herstellung eines arzneimittels zur behandlung von krankheiten, die mit knochenmarködemen assoziiert sind | |
US20050101673A1 (en) | Use of orally available prostacyclin derivatives for the production of a pharmaceutical agent for treating diseases that are associated with bone marrow edemas | |
EP3407899B1 (de) | Immunprophylaxe bei rezidivierenden bakteriellen infektionen | |
EP0484581B1 (de) | Verwendung von Thromboxan-A2-Antagonisten zur Verhinderung von degenerativen Vorgängen im penilen Gewebe | |
CA2219354A1 (en) | Prevention of tooth loss by the administration of alendronate or its salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050103 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1076381 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20060217 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AG |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080318 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1076381 Country of ref document: HK |